Translating Science into Survival - aacr.org Documents/IMM15_PosterSessions... · Angelica Loskog. A042 A predictive nomogram to determine CD137 upregulation on NK cells in patients

CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference:

Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. Biomarkers

A001 Monitoring response to immunotherapy in melanoma by quantification of circulating tumor DNA with droplet digital PCR. Simon Chang-Hao Tsao, Jonathan Weiss, Christopher Hudson, Andreas Behren, Witkowski Tom, Christopher Christophi, Alexander Dobrovic, Jonathan Cebon.

A002 Serum biomarkers of VEGF-A and TGF-β1 predict pathological response and survival of esophageal cancer patients treated with neoadjuvant chemoradiotherapy and esophagectomy. Jason Chia-Hsien Cheng, Yun Chiang, Feng-Ming Hsu, Chiao-Ling Tsai, Chih-Hung Hsu, Jang-Ming Lee.

A003 Polyfunctional antitumor CD8 T cells obtained from a broad repertoire elicited by chemo-immunotherapy and preventing melanoma relapse depends on the activation of an AKT pathway sustained by ICOS. Ornella Franzese , Belinda Palermo, Cosmo Di Donna, Isabella Sperduti, Mariangela Panetta, Maria Laura Foddai , Angela Santoni, Paola Nisticò.

A004 Upregulation of soluble programmed death ligands in patients with colorectal cancer. Jipei Du, Yao Cheng, Zhigang Mao, Shiping Liao, Yanjiang Zheng, Ji Zhang, Yufang Wang.

A005 Flow cytometric profiling the human tumor microenvironment of biopsies and surgical resections to guide clinical development of immunotherapeutics. Mark A Bittinger, Robert E Jones, Mark M Awad, Meghana M Kulkarni, Shohei Koyama, Hajime Asahina, Grit S Herter-Sprie, Christina G Almonte, Abigail A. Santos, Jessie M. English, Julianne Barlow, William G. Richards, Peter S. Hammerman, Scott J Rodig, Raphael Bueno, Kwok-Kin Wong.

A006 Analysis of immune checkpoint control protein co-expression in breast and ovarian cancer using novel rabbit monoclonal antibodies and multiplex IHC. Matthew R Silver, Jennifer E Ziello, Herbert Haack.

A007 Bim as a predictive T cell biomarker for response to anti-PD-1 therapy in metastatic melanoma (MM). Roxana S Dronca, Svetomir N Markovic, Lisa A Kottschade, Wendy Nevala, Haidong Dong.

A008 Discriminant function for predicting survival of lung adenocarcinoma patients developed by using immune parameters of PD-L1, Gal-9 and XAGE1 expression on tumor cells and T cell infiltration score. Yoshihiro Ohue, Kurose Koji, Mikio OKa, Eiichi Nakayama.

A009 IgG4: A new tool to predict the risk of disease progression in melanoma. Panagiotis Karagiannis, Federica Villanova, Debra H Josephs, Isabel Correa, Mieke Van Hemelrijck, Carl Hobbs, Louise Saul, Isioma U Egbuniwe, Isabella Tosi, Kristina M Ilieva, Emma Kent, Eduardo Calonje, Mark Harries, Ian Fentiman, Joyce Taylor-Papadimitriou, Joy Burchel, James F Spicer, Katie E Lacy, Frank O Nestle, Sophia N Karagiannis.

A010 Cancer immunotherapy biomarker profiling assay. Alex Chenchik, Leonid Iakoubov, Michael Makhanov, Costa Frangou.

A011 Gene expression signatures of effector immune cell abundance are significantly associated with recurrence risk in colon cancer. Angela Tatiana Alistar, Julia Chifman, Ralph D'Agostino, Lance D. Miller.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A012 A novel biomarker CRG1 in cetuximab resistant colorectal cancer. Ih-Yeon Hwang, Dae-Hee Lee, Dong-Hoon Jin, Tae-Won Kim.

A013 Biomarker development for cancer immuno-oncology/immuno-therapy: Simultaneous digital counting of nucleic-acids and proteins at 800-plex. Joseph Beechem.

A014 Endogenous anti-β-glucan antibodies and FcgRIIA (CD32a) single nucleotide polymorphisms (SNP) as potential predictive biomarkers for the efficacy of Imprime PGG immunotherapy in cancer patients. Nandita Bose, Anissa Chan, Adria Jonas, Nadine Ottoson, Xiaohong Qiu, Lindsay Wurst, Steven Leonardo, Peter Maimonis, Katie Ertelt, Ben Harrison, Keith Gorden.

Tumor Microenvironment and Cross Talk with the Immune System

A015 Imprime PGG treatment enhances antibody-dependent cellular phagocytosis (ADCP) of tumor cells by monocyte-derived macrophages. Nandita Bose, Adria Jonas, Xiaohong Qiu, Anissa SH Chan, Nadine R Ottoson, Jeremy R Graff.

Biomarkers

A016 T cell landscape within primary melanoma as a predictive biomarker of survival after cancer vaccination in patients with metastatic disease. Angela Vasaturo, Altuna Halilovic, Kalijn Bol, Dagmar Verweij, Patricia Groenen, Han van Krieken, Willeke Blokx, Jolanda de Vries, Johannes Textor, Carl G Figdor.

A017 PD-L1 as a predictive biomarker for atezolizumab (MPDL3280A; anti-PDL1) in non-small cell lung cancer (NSCLC). Marcin Kowanetz, Hartmut Koeppen, Wei Zou, Sanjeev Mariathasan, Matthew Hellmann, Mark Kockx, Colombe Chappey, Edward Kadel, Dustin Smith, Natasha Miley, Vincent Leveque, Roel Funke, Alan Sandler, Ian McCaffery, Lukas Amler, Daniel Chen, Priti Hegde.

A018 Onset of dysthyroidism during treatment with immune checkpoint inhibitors is increased in responder patients. Diego Signorelli , Michele Del Vecchio, Marina Garassino, Alice Intini, Maria Silvia Cona, Michele Magni, Ettore Seregni, Massimo Di Nicola, Filippo De Braud.

A019 Prognostic significance of natural killer ligand expression in acute myeloid leukemia. Rachel Koldej, Jane Ripley, Christopher Chan, Mark Smyth, Paul Neeson, David Ritchie, Travis Perera.

A020 The analyses of immune infiltrate and gene expression of MAGE antigens in bladder cancer allow to explain and predict recurrence. Daniela Fenoglio, Paolo Traverso, Alessia Parodi, Francesca Kalli, Giuseppina Conteduca, Samuele Tardito, Monica Curto, Francesca Ferrera, Federica Grillo, Luca Mastracci, Francesco Minaglia, Alchiede Simonato, Giorgio Carmignani, Gilberto Filaci.

A021 Driver-Map ImmuneNet: A gene expression profiling panel for enumeration of immune and stromal cell admixtures from tissue. Alex Chenchik, Gus Frangou, Leonid Iakoubov.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A022 RNA epigenetics: A new approach to understanding leukemia/lymphoma. Shengdong Ke, James E Darnell, Robert B Darnell.

A023 The clinical utility of the modified Glasgow Prognostic Score in patients undergoing potentially curative colorectal cancer resection. James H Park, Campbell SD Roxburgh, Paul G Horgan, Donald C McMillan.

A024 Protein microarrays for the immunological profiling of melanoma. Jessica Duarte, Janique Peyper, Katherine Woods, Simon Tsao, Georgina Long, Jonathan Cebon, Jonathan Blackburn.

A025 KRAS mutation and IL-22 receptor expression synergistically predict poor prognosis in colorectal cancer. Nathan West, Sarah McCuaig, David Barras, Mauro Delorenzi, Sabine Tejpar, Tim Maughan, Fiona Powrie.

A026 Validation of an assay to identify regulatory T cells by flow cytometry in global clinical trials. Li Zhou, Krista D. Buono, Christina D. Swenson, Michelle Brien, Thomas W. Mc Closkey.

Clinical Trials of Cancer Immunotherapies

A027 A Phase I open-label, non-randomized study of recombinant compound interferon (rSIFN-co) in patients with advanced solid tumors. Su Pin Choo, Wai Meng Tai, Maria Macapagal, Aziah Ahmad, Greg Li, Mui Leng Goh, Matthew Ng, Tira Tan, Shao Weng Tan, Wan Teck Lim.

A028 PEGylated recombinant human IL-10 (AM0010) for advanced solid tumors - a phase 1 study. Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick Alexander Ott, Deborah Jean Lee Wong, Gerrald Stteven Falchook, Manish R. Patel, Shubham Pant, Melinda Whiteside, Johanna C. Bendell, Todd Michael Bauer, Filip Janku, Milind M. Javle, David S. Hong, Martin Oft.

A029 Cell-based cancer immunotherapy using tumor presenting cells: A phase II trial with local advance prostate cancer patients. Fernando T Kreutz.

A030 Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial. Peter Ordentlich, Min-Jung Lee, Yusuke Tomita, Sunmin Lee, Saori Tomita, Scott Cruickshank, Saranya Chumsri, Jane B. Trepel.

A031 CD8+T cells fail to form an effector memory in glioblastoma patients treated with dendritic cell immunotherapy in combination with chemotherapy. Serena Pellegatta, Marica Eoli, Elena Anghileri, Sara Pessina, Carlo Antozzi , Simona Frigerio, Gabriele Cantini, Maria Grazia Bruzzone, Bianca Pollo, Eugenio A. Parati, Gaetano Finocchiaro.

A032 Immunotherapy with ch14.18/CHO in combination with IL2 is active and effective in high-risk relapsed/refractory neuroblastoma patients. Holger N. Lode, Dominique Valteau-Couanet, Alberto Garaventa, Juliet Gray, Victoria Castel, Isaac Yaniv, Nikolai Siebert, Christian Jensen, Stefanie Endres, Lena Pill, Christin Eger, Diana Seidel, Madlen Jüttner, Silke Kietz, Karoline Ehlert, Evelyne Janzek, Carla Manzitti, Ina Müller, Hans Loibner, Ruth Ladenstein.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A033 Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Koji Kurose, Yoshihiro Ohue, Hisashi Wada, Toshihiko Doi, Hiroyoshi Nishikawa, Mikio Oka, Ryuzo Ueda.

A034 Immune responses against tumor associated antigens are induced by treatment with the cell-based tumor vaccine MGN1601 in patients with renal cell carcinoma. Manuel Schmidt, Barbara Volz, Kerstin Kapp, Viktor Gruenwald, Matthias Schroff, Burghardt Wittig.

A035 Pharmacokinetics and pharmacodynamics of the immunotherapeutic TLR-9 agonist MGN1703 – conclusions by comparison of data from clinical trials with healthy volunteers and cancer patients. Manuel Schmidt, Kerstin Kapp, Detlef Oswald, Matthias Schroff, Burghardt Wittig, Alfredo Zurlo.

A036 Anti-PD1 therapy and CD8 T cell invigoration in metastatic melanoma. Alexander Huang, Wei Xu, Shannon Harmon, Felix Quagliarello, Ramin Herati, Kristen Pauken, Bertram Bengsch, Lynn Schuchter, Ravi Amaravadi, Suzanne McGettigan, Tara Gangadhar, John Wherry.

A037 IMCgp100 ImmTAC: A new immunotherapeutic reagent for the treatment of malignant melanoma. Johanne Pentier, Mary Connolly, Martina Canestraro, Ruth Ryan, Luise Weigand, Namir Hassan, Annelise Vuidepot, Bent Jakobsen.

A038 The feasibility of inducing effective systemic immune responses to human metastatic melanoma with intralesional secreted cytokines. Fred T. Valentine, Frederick M. Golomb, Matthew Haris, Daniel F. Roses.

A039 Caspase-2 and oxidative-ER stress crosstalk regulates the exposure of “eat me” signal calreticulin by high hydrostatic pressure treated cancer cells. Irena Kusova Moserova, Iva Truxova, Abhishek G, Garg, Patrizia Agostinis, Piere Francois Cartron, Sarka Vosahlikova, Radek Spisek, Jitka Fucikova.

A040 Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined withchemotherapy in patients with metastatic, castration-resistant prostate cancer. Jitka Fucikova, Michal Podrazil, Rudolf Horvath, Etienne Becht, Jirina Bartunkova, Radek Spisek.

A041 CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia report from the Swedish phase I/IIa trial. Gunilla Enblad, Hannah Karlsson, Kristina I Wikstrom, Magnus Essand, Barbara Savoldo, Malcolm K Brenner, Gianpietro Dotti, Martin Hoglund, Hans Hagberg, Angelica Loskog.

A042 A predictive nomogram to determine CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy. Amani Makkouk, Cariad Chester, Serena Chang, Vandana Sundaram, Manisha Desai, Inna Sayfer, Holden T Maecker, Holbrook E Kohrt.

A043 Safety and efficacy of a genetic vaccine targeting telomerase against various canine cancers. Joseph A Impellizeri, Alessandra Gavazza, George Lubas, Eliana Greissworth, David Jemiolo, Gennaro Ciliberto, Luigi Aurisicchio.

A044 Initial phase I/IIa trial results of an autologous tumor lysate + yeast cell wall particles + dendritic cells vaccine (TLPLDC) in patients with solid tumors. Julia M Greene, Diane F Hale, Erika J Schneble, Xianzhong Yu, Pauline Nichol, Sook Yin, Thomas Wagner, George E Peoples.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A045 Dendritic cell vaccination with partial Treg depletion in relapsed glioblastoma – results from the pilot phase of the HIT-HGG Rez Immunvac study. Matthias Eyrich, Jürgen Krauss, Mario Löhr, Antje Technau, Johannes Rachor, Camelia Monoranu, Monika Warmuth-Metz, Matthias Wölfl, Christof Kramm, Paul Gerhardt Schlegel.

A046 Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM). David A Reardon, Jorg Dietrich, Thomas Kaley, Hui Gan, Gavin P Dunn, Timothy Cloughesy, Michael Lim, Jennifer Clarke, Andrew Park, Linda Pan, Domenic W Lai, Joyson Karakunnel, Paul Robbins, Rajesh Narwal, Ralph Venhaus.

A047 Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Scott Antonia, Naiyer Rizvi, Julie Brahmer, Sai-Hong Ou, Samir N Khleif, Wen-Jen Hwu, Martin Gutierrez, Patrick Schoffski, Omid Hamid, Jared Weiss, Jose Lutzky, Michele Maio, John Nemunaitis, Dirk Jaeger, Ani Balmanoukian, Marlon C Rebelatto, Keith E Steele, Xiaoping Jin, Paul B Robbins, John A Blake-Haskins, Neil H Segal.

A048 Phase 1 clinical trial of a therapeutic prostate cancer vaccine containing PSA/IL-2/GM-CSF in PSA defined biochemical recurrent prostate cancer patients. Jonathan F Head, Gregory A Daniels, Michelle McKinney, Weg Ongkeko, Jessica Wang-Rodriguez, Kyoko Sakamoto, Robert L Elliott.

A049 Demonstration of systemic antitumor immunity via intratumoral regulated expression of IL-12 in advanced breast cancer and melanoma patients. Francois Lebel, John A Barrett, Hongliang Cai, John Miao, Suma Krishnan, Laurence JN Cooper.

A050 Local administration of CpG-B increases recurrence-free survival in early-stage melanoma patients: Long-term follow-up of two randomized clinical trials evaluating adjuvant treatment. Tanja D. de Gruijl, Bas D. Koster, Mari F.C.M. van den Hout, Berbel J.R. Sluijter, Barbara G. Molenkamp, Paul A.M. van Leeuwen, Rik J. Scheper, M. Petrousjka van den Tol, Alfons J.M. van den Eertwegh.

A051 Safety, feasibility and activity of intratumoral injection of activated autologous dendritic cells in solid tumors: A phase I clinical trial. Vivek Subbiah, Ravi Murthy, David S Hong, Robert Prins, Chitra Hosing, Robert Brown, Mary McGuire, Aung Naing, Siquing Fu, Quan Lin, Anthony P Conley, Indreshpal Kaur, Marnix L Bosch.

A052 A clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients; a vaccine to prevent recurrence. Lindy G Durrant, Poulam Patel, Christian Ottensmeier, Clive Mulatero, Paul Lorigan, Rachael Metheringham, Victoria Brentville, Ian Daniels, Drew Hannaman.

Drug Development

A053 Therapy with a non-blocking monoclonal antibody targeting soluble NKG2D ligand MIC revamps endogenous innate and adaptive anti-tumor responses and eliminates primary and metastatic tumors. Jennifer Wu.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. Immune Regulation of T Cell Responses/Evolving Concepts in Cancer Immunology

A054 In vivo characterization of Ipilimumab T cell modulation and anti-tumor activity in a tumor bearing humanized NSG mouse model. Meixia Bi, Chris Hopson, Tianqian Zhang, James smothers, Axel Hoos.

A055 Potent therapeutic and immunological effects of the first T-BiTE derived from a TCR-mimic antibody targeting intracellular oncoprotein WT1. Tao Dao, Dmitry Pankov, Andrew Scott, Tatyana Korontsvit, Victoriya Zakhaleva, Manuel Direito de Morais Guerrerio, Yiyang Xu, Jingyi Xiang, Su Yan, Nicholas Veomett, Nicholas Veomett, Leonid Dubrovsky, Michael Curcio, Ekaterina Doubrovina, Cheng Liu, Richard J. O’Reilly, Richard J. O’Reilly, David A. Scheinberg, David A. Scheinberg, David A. Scheinberg.

A056 Mechanisms of tumor response and resistance to radiation and dual checkpoint blockade in mice and patients. Christina Twyman-Saint Victor, Andrew Rech, Amit Maity, Ramesh Rengan, Kristen Pauken, Kristen Pauken, Erietta Stelekati, Joseph Benci, Bihui Xu, Hannah Dada, Pamela Odorizzi, Ramin Herati, Kathleen Mansfield, Dana Patsch, Ravi Amaravadi, Lynn Schuchter, Hemant Ishwaran, Rosemarie Mick, Daniel Pryma, Xiaowei Xu, Michael Feldman, Tara Gangadhar, Stephen Hahn, E. John Wherry, Robert Vonderheide, Andy Minn.

A057 Uni-CIDeCAR-T cells: MyD88/CD40-enhanced, Ab-directed CAR incorporating the CaspaCIDe® safety switch. MyLinh T Duong, Matthew R Collinson-Pautz, Aaron E Foster, J Henri Bayle, David M Spencer.

A058 GITRL-Fc, an immunotherapeutic agent that stimulates T-cell-mediated antitumor immune response. Fumiko Axelrod, Hyun-Bae Jie, Erin Mayes, Jorge Monteon, Minu Srivastava, Rui Yun, Inkyung Angie Park, Austin Gurney.

A059 Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Kutlu Elpek, Christopher Harvey, Ellen Duong, Tyler Simpson, Jenny Shu, Lindsey Shallberg, Matt Wallace, Sriram Sathy, Robert Mabry, Jennifer Michaelson, Michael Briskin.

A060 Immunoproteasome deficiency is a feature of NSCLC with a mesenchymal phenotype and is associated with restricted antigen presentation and poor outcome in patients. Satyendra C Tripathi, Haley L Peters, Edwin J Ostrin, Ayumu Taguchi, Hiroyuki Katayama, Hong Wang, Amin Momin, Mohit K Jolly, Muge Celiktas, Jaime Rodriguez, Carmen Behrens, Ignacio I Wistuba, Eshel Ben Jacob, Herbert Levine, Jeffrey J Molldrem, Samir M Hanash.

A061 Tumor cell expression of PD-L1 is important in determining the in vivo fate of edited MCA sarcomas. Takuro Noguchi, Jeffrey P Ward, Matthew M Gubin, Cora Arthur, Robert D Schreiber.

A062 Anti-LAP antibody promotes a tumor-specific immune response by targeting regulatory T cells and TGF-β. Galina Gabriely, Andre da Cunha, Brendan Kenyon, Rafael Rezende, Murugaiyan Gopal, Tyler Vandeventer, Howard L Weiner.

A063 Cancer cell expression of CCR2 regulates the PD-L1/ PD-1 immune checkpoint in breast cancer. Miriam R Fein, Ana S. Almeida, Anaïs Eberhardt, Mikala Egeblad.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A064 Modeling checkpoint blockade inhibitor resistant immunoregulation induced by squamous epithelial cancers. Stephen Mattarollo, Graham Leggatt, James Wells, Paul Lambert, Ian H Frazer.

A065 Genome-wide analysis of the cytosolic DNA sensing pathway. Chan-Wang J. Lio, Jenny Huang, Anjana Rao* equal contribution, Sonia Sharma* equal contribution.

A066 Histone deacetylase 11 is an epigenetic regulator of T-cell pro-inflammatory function and novel target for enhancing T-cell antitumor activity. David M Woods, Andressa L Sodre, Karrune Woan, Alejandro Villagra, Amod Sarnaik, Jeffrey Weber, Eduardo M Sotomayor.

A067 Quality of initial activation of CD8 T cells specific for TRP1 determines long-term anti-tumor immunity. Paul Tyler, Mariah Servos, Stephanie K Dougan.

A068 Imbalance in regulatory T (Treg) cells frequency in peripheral circulation of patients with oral squamous cell carcinoma and their effects on growth of oral cancer. Sadhna Aggarwal, Satya N Das, Suresh C Sharma.

A069 T-cell motility is controlled by homotypic interactions and serves as a biomarker for anti-tumor polyfunctionality. Navin Varadarajan, Ivan Liadi, Gabrielle Romain, Harjeet Singh, Laurence Cooper, Badrinath Roysam.

A070 Genetic knockdown screens across tumor types unravel a diverse tumor immune-modulatome landscape. Nisit Khandelwal, Tillmann Michels, Marco Breinig, Antonio Sorrentino, Isabel Poschke, Rienk Offringa, Michal Lotem, Michael Boutros, Philipp Beckhove.

A071 Immune monitoring of ipilimumab treated patients reveals enhanced CD4+ T cell activation correlated with diminished MDSCs. Yago Pico de Coaña, Maria Wolodarski, Yuya Yoshimoto, Giusy Gentilcore, Isabel Poschke, Giuseppe V Masucci, Johan Hansson , Rolf Kiessling.

A072 Reprogramming immune response with capsid-optimized AAV vectors for immunotherapy of cancer. Munjal Pandy, Kellee Britt, George Aslanidi.

A073 Carrier-free delivery of cytokine to specifically expand adoptively transferred T cells for enhanced cancer immunotherapy. Li Tang, Yiran Zheng, Llian Mabardi, Darrell J Irvine.

A074 Selective inhibition of HDAC6 augments T-cell central memory and enhances antitumor functions: Implications in TIL therapy. Andressa Sodre Laino, David M Woods, Amod Sarnaik, Jeffrey Weber, Eduardo M Sotomayor.

A075 Immunotherapy of malignant pleural mesothelioma using cMET specific T-cells. Thivyan Thayaparan, Sjoukje J.C. van der Stegen, Ana C Parente Pereira Puri, Roseanna Maria Petrovic, James Spicer, John Maher.

A076 CD40 stimulation overrides role of innate immune sensors for priming of T cells in cancer. Katelyn T Byrne, Robert H Vonderheide.

A077 Unraveling predicted immunomodulatory effects of novel cancer-associated noncoding RNAs. Antoine Tanne, Luciana Muniz, David Ting, Arnold Levine, Nina Bhardwaj, Benjamin Greenbaum.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A078 Computational discovery and experimental validation of novel drug targets in immuno-oncology. Arthur Machlenkin, Ofer Levy, Galit Rotman.

A079 Inhibition of HSP90 improves response to α-CTLA4 immunotherapy in melanoma. Rina M Mbofung, Shruti Malu, Jodi A McKenzie, Rodabe N Amaria, Patrick Hwu.

A080 Targeted genome modifications for improved adoptive immunotherapy. Julien Valton, Anne-Sophie Gautron, Alexandre Juillerat, Philippe Duchateau, Laurent Poirot.

A081 A PD-L1-targeted Probody provides antitumor efficacy while minimizing induction of systemic autoimmunity. Chihunt Wong, Li Mei, Kenneth R Wong, Elizabeth E.M. Menendez, Olga Vasiljeva, Jennifer H Richardson, James W West, Michael Kavanaugh, Bryan A Irving.

A082 Developing a PD-1 based inhibitory chimeric antigen receptor (ICAR) for co-expression, to overcome off-tumor toxicity when targeting ErbB2 using engineered T cells. Roseanna Maria Petrovic, Scott Wilkie, John Maher.

A083 Modulation of the immune system as a strategy to treat EGFR mutant lung adenocarcinoma. Deborah Ayeni, Ping-Chih Ho, Curtis Perry, Susan Kaech, Katerina Politi.

A084 Identification of mutation-reactive T cells in patients with gastrointestinal cancers. Mélissa Mathieu, Sandy Pelletier, David Laperrière, Sylvie Mader, Simon Turcotte.

A085 Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary clear cell renal cell cancer. Nicolas A Giraldo, Becht Etienne, Laetitia Lacroix, Yann Vano, Rafael Sanchez-Salas, Pierre Validire, Virginie Verkarre, Arnaud Mejean, Marie-Caroline Dieu-Nosjean, Stephane Oudard, Xavier Cathelineau, Wolf H Fridman, Catherine Sautès-Fridman.

A086 Real-time in vivo characterization of spatiotemporal immunotherapeutic response to high intensity focused ultrasound with a novel NF-kB reporter model of human breast cancer. Mary D Dockery, Megan E Poorman, Vandiver L Chaplin, Ryan A Spears, Charles F Caskey, William A Grissom, Todd D Giorgio.

A087 Phase separation of signaling molecules promotes T cell receptor signal transduction. Xiaolei Su, Jon Ditlev, Enfu Hui, Sudeep Banjade, Julia Okrut, Jack Taunton, Mike Rosen, Ron Vale.

A088 Increase lymphocyte infiltration overcomes tumor resistance to checkpoint blockade. Haidong Tang, Yang Wang, Yang-Xin Fu.

A089 The circulating memory B cell compartment of breast cancer patients is depleted in comparison with healthy volunteers. Matthew W Fittall, Dina Levi, Angela Clifford, Vandna Shah, Anthony Cheung, Andrew Tutt, Sophia N Karagiannis.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. Tumor Antigens for Targeting: Insight from Genomics

A090 Exploring folate receptor α immunotherapy of breast carcinomas: Human monocytic cell-mediated killing triggered by IgG1 and IgE antibodies. Matthew W Fittall, Anthony Cheung, Gyula M Petranyi, Diana Rodriguez-Dominguez, Heather J Bax, Panagiotis Karagiannis, Kristina M Ilieva, Andrew Tutt, Sophia N Karagiannis.

Immune Regulation of T Cell Responses/Evolving Concepts in Cancer Immunology

A091 Targeting the TGFb pathway with galunisertib, a TGFbRI SMI, promotes antitumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition. David Schaer, Yanxia Li, Stephen Castaneda, Ivan Inigo, David Surguladze, Xiaohong Xu, Desiree Nugent, Mary Murphy, Gerald Hall, Karim Benhadji, Susan Guba, Yiwen Li, Michael Kalos, Kyla Driscoll.

A092 Surpassing the emerging immune-checkpoint inhibitor market. Michael P Vitek.

A093 Interferon gamma and post-translational modifications control the dynamics and plasma membrane association of IL15RA expressed by triple negative breast cancer (TNBC). Pierfrancesco Marra, Sumi Mathew, Steven Catchpole, Alessandra Facchetti, Andrew Tutt.

A094 IL-2 complex rescues CD8+ T cell tolerance for cancer immunotherapy. Lauryn E Swier, Melissa M Berrien-Elliott, Ryan M Teague.

A095 New genes for enhancing T cell function in adoptive cell therapy of cancer. Gideon Gross, Aviad Pato, Hadas Weinstein-Marom, Noam Levin, Alon Margalit, Orit Itzhaki, Michal Besser, Tamar Peretz, Arthur Machlenkin, Michal Lotem.

A096 CX3CR1 expression levels distinguish CD8+ memory T cells surveying non-lymphoid tissues from effector memory and central memory T cells. Carmen Gerlach, E. Ashley Moseman, Scott M Loughhead, David Alvarez, Anthonie J Zwijnenburg, Lisette Waanders, Ulrich H von Andrian.

A097 Potentiating adoptive T cell therapy through orthogonal cytokine-receptor engineering. Jonathan T Sockolosky, Jamie Spangler, Melissa McCracken, Chris King, David Baker, K. Christopher Garcia.

Microbiome

A098 Helicobacter-specific T cell responses in gut homeostasis and disease. Mo Xu, Dan R. Littman.

A099 Tracking microbial sensing in colorectal cancer using bioorthogonal click chemistry. Jason Hudak, Naama Geva-Zatorsky, Dennis L. Kasper.

A100 Cooperative defense against acute Clostridium difficile infection is mediated by two Innate Lymphoid Cell subsets. Michael C Abt, Brittany B Lewis, Lilan Ling, Rebecca A Carter , Boj Susac, Eric G Pamer.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A101 Antitumor efficacy of anti-CTLA4 antibody is dependant on gut microbiota. Marie Vetizou, Jonathan Pitt, Romain Daillere, Laurence Zitvogel.

A102 The effect of defined skin resident commensals in skin immunity. Vanessa K Ridaura, Jan Claesen, Michael A Fischbach, Yasmine Belkaid.

A103 Regulation of Toll-like receptor expression in intestinal epithelial cells. April Price, Greg Barton.

Preclinical Models

A104 Eradication of large solid tumors in immunocompetent mice using dual specific CAR T cells and vaccination. Clare Y Slaney, Jennifer A Westwood, Paul A Beavis, Phillip K Darcy, Michael H Kershaw.


A105 Cross-talk between tumors can affect responses to therapy. Christel Devaud, Jennifer A Westwood, Liza John, Carmen SM Yong, Paul A Beavis, Linda A Snyder, Reto A Schwendener, Darcy K Phillip, Michael H Kershaw.

Tumor Antigens for Targeting: Insight from Genomics

A106 Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens. Todd D. Prickett, Jessica Crystal, Jared Gartner, Xin Yao, Anna Pasetto, Alena Gros, Yong-Chen Lu, Yong F. Li, Mona El-Gamil, Steven A. Rosenberg, Paul Robbins.

A107 Ewing sarcoma preferentially express CD99 isoform variant 5 compared to normal tissues. Sabine Heitzeneder, John F Shern, Javed Khan, Crystal L Mackall.

A108 Expitope: A webserver for epitope expression. Silke Raffegerst, Kerstin Haase, Maja Buerdek, Christian Ellinger, Dmitrij Frishman, Dolores Schendel.

A109 Exploring neoantigens and immunological response in GBM patients after individualized Prophage vaccination. John Castle, Dan Levey, Elise Drouin, Nicholas Wilson, Steven Schoenfeld, Orin Bloch, Jennifer Buell.

A110 Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Mathias Vormehr, Sebastian Kreiter, Niels van de Roemer, Mustafa Diken, Martin Löwer, Fulvia Vascotto, Jan Diekmann, Sebastian Boegel, Barbara Schroers, Arbel D. Tadmor, Özlem Türeci, Ugur Sahin.

A111 The immunopeptidomic landscape of ovarian carcinoma. Heiko Schuster, Janet Peper, Kevin Roehle, Hans-Georg Rammensee, Stefan Stevanovic, Philipp Wagner.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A112 Mapping the impact of proteasome inhibitor therapy on the antigenic landscape of multiple myeloma: Identifying robust targets for T cell immunotherapy. Daniel J Kowalewski, Simon Walz, Linus Backert, Heiko Schuster, Oliver Kohlbacher, Lothar Kanz, Helmut R Salih, Hans-Georg Rammensee, Stefan Stevanovic, Juliane S Stickel.

A113 iVacALL: A personalized peptide-vaccination design platform for pediatric acute lymphoblastic leukemia patients based on patient-individual tumor-specific variants. Armin Rabsteyn, Christina Kyzirakos, Christopher Schröder, Marc Sturm, Christopher Mohr, Mathias Walzer, Ulrike Pflückhahn, Michael Walter, Magdalena Feldhahn, Karoline Laske, Michael Bonin, Martin Ebinger, Stefan Stevanovic, Stefan Stevanovic, Peter Bauer, Oliver Kohlbacher, Cecile Gouttefangeas, Cecile Gouttefangeas, Hans-Georg Rammensee, Hans-Georg Rammensee, Rupert Handgretinger, Rupert Handgretinger, Peter Lang, Peter Lang.

A114 Towards personalized cellular adoptive immunotherapy targeting tumor specific neoantigens in microsatellite unstable colorectal cancers. Pauline Maby, Mohamad Hamieh, Hafid Kora, David Tougeron, Bernhard Mlecnik, Gabriela Bindea, Helen K Angell, Tessa Fredriksen, Nicolas Elie, Emilie Fauquembergue, Aurélie Drouet, Jérôme Leprince, Jacques Benichou, Jacques Mauillon, Florence Le Pessot, Richard Sesboüé, Thierry Frébourg, Jérôme Galon, Jean-Baptiste Latouche.

A115 Cancer vaccine development for hepatocellular carcinoma – HEPAVAC. Luigi Buonaguro, Sarah Kutscher, Roberto Accolla, Yuk T. Ma, Regina Heidenreich, Francesco Izzo, Alfred Koenigsrainer, Markus Loeffler, Phillip Mueller, Andrea Mayer, Hans-Georg Rammensee, Bruno Sangro, Sven Francque, Danila Valmori, Toni Weinschenk, Harpreet Singh-Jasuja.

A116 A predictive model to identify immunogenic neoepitopes in patients with melanoma treated with CTLA-4 blockade. Diego Chowell, Sri Krishna, Alexandra Snyder, Makarov Vladimir, Timothy A. Chan, Karen S. Anderson.

A117 Novel and shared neoantigen for glioma T cell therapy derived from histone 3 variant H3.3 K27M mutation. Yafei Hou, Gary Kohanbash, Kaori Okada, Shruti Shrivastav, Matthew Smith-Cohn, Theodore Nicolaides, Sabine Mueller, Angel Montero Carcaboso, Ian F Pollack , Hideho Okada.


A118 Transforming growth factor-beta as a therapeutic target for pancreatic cancer. Ismail Meraz, Leoncio Vergara, Sarah Suki, Prem Siddharth Gunamalai, Rita Elena Serda.

A119 Antibody blockade of Semaphorin 4D neutralizes barrier to immune infiltration and facilitates immune-mediated tumor rejection. Elizabeth E Evans, Holm Bussler, Sebold Torno, Crystal Mallow, Laurie A Winters, Christine Reilly, Ekaterina Klimatcheva, Janaki Veeraraghavan, Alan S Jonason, Maria Scrivens, Renee Kirk, Alan Howell, Leslie Balch, John E Leonard, Mark Paris, Terrence L Fisher, Ernest S Smith, Maurice Zauderer.

A120 Tumor educated B cells acquire LAP/TGF-β1 and PD-L1 expression and suppress antitumor immune response. Yu Zhang, Richard Morgan, Chuan Chen, Yancheng Cai, Seung-Uon Shin, Hyun-Mi Cho, Ahmed Al Bayati, Augustin Pimental, Joseph D Rosenblatt.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A121 Complement activation is critical for tumor progression in an orthotopic immunocompetent model of lung cancer. Jeff Kwak, Howard Li, Jennifer Laskowski, Mary Weiser-Evans, Joshua Thurman, Raphael A Nemenoff.

A122 Non-small cell lung cancer cells induce PD-L1 expression in the tumor microenvironment in an orthotopic mouse model of lung cancer. Howard Li, Maria McSharry, Eric Clambey, Teresa Nguyen, Eoin McNamee, Mary Weiser-Evans, Raphael Nemenoff.

A123 CD14+ monocyte recruitment, transformation and support of tumor survival in a lung cancer model. Erin Schenk, Allan Dietz.

A124 Tertiary lymphoid structures: Predictors of effective anti-tumor immunity in human breast cancer? Soizic Garaud, Laurence Buisseret, Chunyan Gu-Trantien, Gert Van den Eynden, Alexandre de Wind, Edoardo Migliori, Roberto Salgado, Denis Larsimont, Martine Piccart, Karen Willard-Gallo.

A125 Breaking the tension: Investigating a link between tissue mechanics and tumor immunity in breast cancer. Ori Maller, Luke Cassereau, Jason Northey, Brian Ruffell, Ryan Hill, Miranda L Broz, Jennifer M Munson, Melody A Swartz, Kirk C Hansen, Matthew F Krummel, Lisa M Coussens, Valerie M Weaver.

A126 Taking out the trash: Efferocytosis in the tumor microenvironment. Rebecca S Cook.

A127 Innate crosstalk between ILC and interstitial macrophages promotes lung cancer regression in response to IL-12 therapy. Jake Y Henry, Frederick Arce, Burkhard Becher, Karl S Peggs, Sergio A Quezada.

A128 Suppression of anti-tumor immune responses in tumor-associated tertiary lymphoid structures by regulatory T cells. Nikhil S Joshi, Tyler Jacks.

A129 Tumor-associated lymphatic vessels as a biomarker of antitumor immunity. Ryan Lane, Jamie Booth, Christopher Loo, Amanda W Lund.

A130 Immune regulation of EMT and metastatic competence in breast tumor progression. Robiya Joseph, Rama Soundararajan, Anurag Paranjape, Sendurai Mani.

A131 Measurement of immune infiltration in ER, PR, and HER2 IHC subtypes reveals populations that may benefit from immunotherapy. Pinky Tripathi, Nam Tran, Raghavkrishna Padmanabhan, Richard Hartsfield, Edward J Moler, Nicholas Hoe, Kenneth Bloom.

A132 Nonalcoholic fatty liver disease causes selective CD4+ lymphocytes loss and promotes hepatocarcinogenesis. Chi Ma, Aparna Kesarwala, Daniel McVicar, Achim Weber, Mathias Heikenwaelder, Tim Greten.

A133 Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sections. James R Mansfield, Clifford C Hoyt, Edward Stack, Michael Feldman, Carlo Bifulco, Bernard Fox.

A134 The immunoregulatory enzyme IDO induces resistance to common chemotherapy drugs via base excision repair pathway. Saman Maleki Vareki, Chen Di, Christine Di Cresce, Peter J Ferguson, Mark Vincent, Weiping Min, Xiufen Zheng, James Koropatnick.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A135 Phosphodiesterase-5 inhibition augments postoperative natural killer cell antitumor immunity by reducing myeloid-derived suppressor cell function. Lee-Hwa Tai, Almohanad A Alkayyal, Christiano Tanese de Souza, Amanda Lynn Leslie, Shalini Sahi, Sean Bennett, Jiqing Zhang, John C Bell, Rebecca A Auer.

A136 Myeloid cells regulate pancreatic carcinogenesis and remodeling. Yaqing Zhang, Wei Yan, Esha Mathew, Kevin T Kane, Marina Pasca di Magliano.

A137 Multi-modal treatment with peptide vaccine, metronomic cyclophosphamide and PD-1 blockade provides effective tumor control through a mechanism of epitope spreading. Genevieve M Weir, Olga Hrytsenko, Marianne Stanford, Mohan Karkada, Neil Berinstein, Marc Mansour.

A138 Identification of key immune regulators that control obesity-induced liver inflammation and diseases. Zhenyu Zhong, Atsushi Umemura, Shuang Liang, Michael Karin.

A139 Adenosine regulates in situ tumor vaccination by radiation therapy. Erik Wennerberg, Noriko Kawashima, Sandra Demaria.

A140 Viral-like nanoparticles for tumor immunotherapy by in situ vaccination mediate potent antitumor immunity. Patrick Lizotte, Amy Wen, NIcole Steinmetz, Steven Fiering.

A141 The vigorous immune microenvironment of microsatellite instable colon cancer isbalanced by multiple counter-inhibitory checkpoints. Nicolas J Llosa, Franck Housseau, Elizabeth Wick, Hechenbleikner Lizzy, Michael Cruise, Robert Anders, Cynthia Sears, Drew M Pardoll, Hongni Fan, Nicholas Siegel, Lee Blosser, Ada Tam, Hao Wang.

A142 An in vivo functional genomics screen identifies molecular determinants of adaptive immune rejection. Casey W Shuptrine, Elana J Fertig, Marsha Salcie-Gautreaux, Louis M Weiner.

A143 Melanoma cell resistance to phagocytosis is unrelated to expression of conventional “eat-me/don’t eat-me” signals. Katie L Anderson, Debra Lins, Jens-Peter Volkmer, Yoji Shimizu, Irving L Weissman, Matthew Mescher, Jaime Modiano.

A144 Cooperative effects of TGFβ and activin A control regulatory T cell numbers in irradiated tumors. Claire I Vanpouille-Box, Silvia Formenti, Sandra Demaria.

A145 Radiation therapy induces tumor-promoting immune suppression in the microenvironment of pancreatic carcinoma. Lena Tomkötter, Gregor Werba, Susanna Nguy, Sara Alothman, Dalia Alqunaibit, Shaun Tiwari, Nancy Ngoc Giao Ly, Donnele Daley, Atsuo Ochi, Rocky Barilla, Alejandro Torres-Hernandez, Ilenia Pellicciotta, Kevin Du, George Miller.

A146 The role of SOCS-1 in stimulating melanoma development through tyrosine-kinase receptors and MAPK pathways and prevents antitumour immunity by PD-L1 expression. Rodrigo Berzaghi, Vera SC Maia, Felipe V Pereira, Filipe Manegatti De Melo, Luiz R. Travassos, Luiz R. Travassos.

A147 Sunitinib upregulates IFNγ-STAT1 signaling to modulate the tumor immune microenvironment in renal cell carcinoma. Xian-De Liu, Anh Hoang, Mianen Sun, Zhou Lijun, Zhiyong Ding, Xuesong Zhang, Shanshan Bai, Nizar Tannir, Eric Jonasch.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A148 Protecting CAR T cells from immunosuppressive cytokines present in the tumor microenvironment. Sujita Sukumaran, Somala Mohammed, Norihiro Watanabe, Pradip Bajgain, Helen E Heslop, Cliona M Rooney, Malcolm K Brenner, Ann M Leen, Juan F Vera.

A149 Evaluating immune contexture in syngeneic mouse models of cancer. Sapna Yadavilli, Sabyasachi Bhattacharya, Ashleigh Hahn, Laura Seestaller-Wehr, David Kilian, Meixia Bi, Shu-Yun Zhang, Nicholas Vitali, Michael Adam, Yufeng Li, Niranjan Yanamandra, Roopa Srinivasan, Axel Hoos.

A150 Tertiary lymphoid structures in non-small cell lung cancer and effects of chemotherapy. Karina Silina, Alex Soltermann, Farkhondeh Movahedian Attar, Ruben Casanova, Periklis Foukas, Aija Line, Maries van den Broek.

A151 Radiation-induced TGFβ regulates the myeloid compartment to suppress antitumor immunity. Alba Gonzalez Junca, Ilenia Pellicciotta, Kyla Driscoll Carroll, David Schaer, Mary Helen Barcellos-Hoff.

A152 The Macrophage Migration Inhibitory Factor promotes breast cancer metastasis through interaction with the host immune response. Kristen N Balogh, Janet V Cross.

A153 Targeting immune therapy for childhood ependymoma. Andrea M Griesinger, Rebecca J Josephson, Andrew M Donson, Jean M Mulcahy Levy, Vladimir Amani, Diane K Birks, Lindsey M Hoffman, Steffanie L Furtek, Philip Reigan, Michael H Handler, Rajeev Vibhakar, Nicholas K Foreman.

A154 Downregulation of Spin90 in stromal fibroblasts promotes cancer metastasis by remodeling tumor microenvironment. Yun Hyun Huh, Ah-reum Kwon, Je-Hwang Ryu, Woo Keun Song.

A155 Unmasking cancer to innate sensing by anti-CD47 antibody triggers adaptive immune-mediated destruction of immunogenic tumors. Meng Xu.

Other

A156 Anti-p53 auto-antibody serum profiling using high-density peptide arrays. Ken C Lo, John C. Tan, Eric Sullivan, Ryan Bannen, Todd Richmond, Florian Grupp, Stefan Weiser, Dieter Heindl, Klaus-Peter Stengele, Albert Thomas.

A157 Oncolytic poliovirus mediated immune events. Michael C Brown, Eda K Holl, David Boczkowski, Darell D Bigner, Matthias Gromeier, Smita K Nair.

A158 MAGED4B specific peptides: short or long or combination? Kue Peng Lim, Ai Leng Chun, Sathibalan Ponniah, Sok Ching Cheong.

A159 Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A meta-analysis of randomized controlled trials. Tomohiro Funakoshi, Hyman Muss, Stergios Moschos.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A160 Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity. Steven M Leonardo, Ross B Fulton, Lindsay R Wurst, Keith B Gorden, Adria Bykowski Jonas, Xiaohong Qui, Anissa SH Chan, Jeremy R Graff.

A161 Angiotensin II type 1 receptor antagonism suppresses tumor metastasis through inhibition of CCL2-CCR2 mediated monocyte recruitment. Daniel P Regan, Amanda M Guth, Ryan J Hansen, Daniel L Gustafson, Steven W Dow.

A162 Cancer-specific T cell receptor isolation for cancer immunotherapy. Ruth Ryan, Linda Hibbert, Luise Weigand, Samantha Paston, Debbie Baker, Zoe Donnellan, Vanessa Clark, Kathy Hale, Louise Conlon, Joseph Dukes, Caroline Boudousquie, Giovanna Bossi, Emma Hickman, Alex Powlesland, Annelise Vuidepot, Namir Hassan, Bent Jakobsen.

A163 Tertiary lymphoid structures: Prognostic significance and relationship with tumor-infiltrating lymphocytes in triple-negative breast cancer. In Ah Park, Hee Jin Lee, In Hye Song, Joo Young Kim, Jong Han Yu, Gyungyub Gong.

A164 Genetically modified cytokine-induced killer (CIK) cells for targeted cancer therapy. Sarah Oelsner, Juliane Wagner, Miriam E Friede, Verena Pfirrmann, Eva Rettinger, Ralf Schubert, Heike Pfeifer, Evelyn Ullrich, Peter Bader, Winfried S Wels.

A165 Engineering approaches to uncover the mechanism of apoptotic cell clearance by a conserved signaling system. Adam Williamson, Ron Vale.

A166 Biogenesis and regulatory functions of super-enhancer RNAs in cancer cells of the immune system. Yang Eric Guo, Richard Young.

A167 Functional analysis of DNA sensors in the interferon stimulatory DNA (ISD) Pathway. Elizabeth Gray, Daniel Stetson.

A168 Towards an understanding of the structural basis of CXCR7 ligand binding and signaling. Martin Gustavsson, Yi Zheng, Ling Qin, Lauren G Holden, Irina Kufareva, Tracy M Handel.

A169 NY-ESO-1 protein cancer vaccine with TLR 3 and 4 agonists. Tomohira Takeoka, Hirotsugu Nagase, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Yukinori Kurokawa, Tomoki Makino, Makoto Yamasaki, Shuji Takiguchi, Masaki Mori, Yuichiro Doki, Hisashi Wada.

A170 The mode of action of Orf virus – a novel viral vector for therapeutic cancer vaccines. Melanie Mueller, Ralf Amann, Thomas Feger, Hans-Georg Rammensee.

A171 Long-term episomal gene transfer for safe engineering of T-cells for adoptive cell therapy of cancer. Chuan Jin, Mohanraj Ramachandran, Grammatiki Fotaki, Berith Nilsson, Magnus Essand, Di Yu.

A172 Allogeneic dendritic cells (AlloDCs) transduced with an infection-enhanced adenovirus as adjuvant for cancer immunotherapy. Grammatiki Fotaki, Chuan Jin, Alex Karlsson-Parra, Di Yu, Magnus Essand.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A173 Inhibition of the STING pathway by the AIM2 inflammasome. Leticia Corrales, Seng-Ryong Woo, Thomas F Gajewski.

A174 Mechanistic Elucidation of Activation-induced Deaminase (AID) in Immunity and Cancer. Qi Qiao, Li Wang, Feilong Meng, Hao Wu.

A175 Design and evaluation of novel natural killer cell chimeric antigen receptors. David L Hermanson, Branden Moriarity, Trevor Argall, Melissa A Geller, David Largaespada, Dan S Kaufman.

A176 Efficacy and safety of allogeneic double negative T cell as anti-AML therapy and its underlying mechanism. Jong Bok Lee, Claire Weihsu Chen, Mark D Minden, John E Dick, Li Zhang.

A177 2’-5’ oligoadenylates mediate innate immune crosstalk between antiviral RNA and DNA sensors. Jonathan M Clingan, Sterling C Eckard, Daphne A Cooper, Hilario J Ramos, Jaime Guillen, Bruno Canard, Michael Gale, Jay R Hesselberth, David J Barton, Joshua J Woodward, Daniel B Stetson.

A178 Oncolytic rhabdovirus and inhibitor of apoptosis (IAP) protein antagonist for cancer therapy. Dae-Sun Kim, Himika Dastidar, Keith Lau, Chunfen Zhang, Douglas J Mahoney.

A179 Ex-vivo generation of clinical grade T cells by using activating and propagating feeder cells to cross-link T cell receptor. Bipulendu Jena, Hiroaki Taguchi, Aleksandra Nowicka, Ana B Korngold, Helen Huls, Laurence JN Cooper.

A180 Topologically associated domains genome-wide restrict the off-target activity of recombination activating gene 1/2 endonuclease. Jiazhi Hu, Yu Zhang, Lijuan Zhao, Richard Frock, Zhou Du, Robin M Meyers, Feilong Meng, David G Schatz, Frederick W Alt.

A181 Dissecting the spatiotemporal functions of WAVE complex during chemotaxis using CRISPR and optogenetics. Brian R Graziano, Orion D Weiner.

A182 Zbtb7b is involved in the association of EBF1 enhancer to the nuclear lamina during early B cell commitment. Yina Zhu, Cornelis Murre.

A183 Molecular elucidation of the CBM complex in NF-kappaB activation by using single molecule imaging and structural studies. Liron David, Hao Wu.

A184 Listeria-32P, a new approach to treat pancreatic cancer. Dinesh Chandra, Ziqiang Yuan, Steven K Libutti, Ekaterina Dadachova, Claudia Gravekamp.

A185 Hypercholesterolemia impairs immunosurveillance against colorectal cancer by inhibiting Tet1 dependent differentiation of HSCs towards NKT and gammadelta T cells. Guodong Tie, Jinglian Yan, Julia Messina, April Deng, Sarah Hainer, Joonsoo Kang, Thomas Fazzio, Louis Messina.

A186 Development of novel lipid based adjuvants and bacterial vector systems for cancer immunotherapy. Lakshmi Krishnan, Rahul Kushwah.

A187 Genome-wide screening of programmed cell death pathways. Will Bailis, Ruaidhri Jackson.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session A, Wednesday, September 16, 2015, 6:45 p.m.-8:45 p.m. A188 The effects of cellular context on miR-155 mediated regulation of gene expression. Jing-Ping Hsin, Yuheng Lu, Gabriel B. Loeb, Christina S. Leslie, Alexander Y. Rudensky.

A189 Direct antimicrobial and cytotoxic activity of mucosal activated invariant T cells. Yvonne K Mburu, Flavia Castellano, Valérie Moliner-Frenkel, Olivier Lantz.

A190 VSV-GP in single and combination therapy is a potent oncolytic virus platform for the treatment of melanoma. Zoltan Banki, Iris Koske, Reinhard Tober, Carles Rodriguez Urbiola, Isabel Barnstorf, Alexander Muik, Lisa Egerer, Janine Kimpel, Dorothee von Laer, Guido Wollmann.

A191 Augmenting the therapeutic efficacy of oncolytic LCMV-GP pseudotyped Vesicular Stomatitis Virus via modulation of the innate immune system. Carles Rodriguez Urbiola, Catherine Dold, Janine Kimpel, Christian Marth, Frederic Santer, Zoran Culig, Alexander Muik, Tanja Knapp, Ira Winkler, Guido Wollmann, Dorothee Von Laer, Patrik Erlmann.

A192 Oscillatory genes involved in lymphocyte retention and egress. Hsin Chen, Timothy Schmidt, Ying Xu, Jason G Cyster.

A193 Bioengineered Dectin-1 CAR+ T cells to control invasive fungal infection. Pappanaicken R Kumaresan, Nathaniel Albert, Harjeet Singh, Simon Olivares, Sourindra N Maiti, Tiejuan Mi, Helen Huls, Richard E Champlin, Dimitrios P. Kontoyiannis, Laurence J.N. Cooper.

A194 Delta-24-RGDOX: expressing OX40L in gliomas using replication competent oncolytic adenoviruses induces anti-tumor effect and anti-glioma immune memory. Hong Jiang, Candelaria Gomez-Manzano, Karen Clise-Dwyer, Laura Bover, Luis M Vence, Frederick F Lang, Charles A Conrad, Carlo Toniatti, Frank Tufaro, Juan Fueyo.

Clinical Trials of Cancer Immunotherapies

A195 Tremelimimab activates CD4 and CD8+ T cells in patients with hepatocellular carcinoma. Firouzeh Korangy, Mei ElGindi, Drew Pratt, David Venzon, Austin Duffy, Oxana Makarova-Rusher, Sid Kerkar, David Kleiner, Bradford Wood, Tim Greten.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m.

Companion Diagnostics: Assay Harmonization

B001 Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab. Zachary S Boyd, Dustin Smith, Brian Baker, Bharathi Vennapusa, Hartmut Koeppen, Marcin Kowanetz, Sanjeev Mariathasan, Jean-Marie Bruey, Howard Mackey, Gregg Fine, Simonetta Mocci, Priti Hegde, J. Andrew Williams, Ian McCaffery.

B002 Automated target antigen characterization on residual leukemic cells by flow cytometry. Thomas Köhnke, Sandra Rechkemmer, Veit Leonhard Bücklein, Wolfgang Hiddemann, Marion Subklewe.

B003 Developing an analytical method for second messenger cyclic GMP-AMP. Tuo Li, Zhijian J Chen.

B004 The importance of quality standards to support test performance for the purpose of treatment decision making. Anita Midha, Jill Walker, Marlon C Rebelatto, Costi Sabalos, amita Mistry, Nicole Schechter.

B005 An immunohistochemical PD-L1 companion diagnostic assay for treatment with durvalumab (MEDI4736) in NSCLC patients. Marlon C Rebelatto, Amita Mistry, Constantine Sabalos, Nicole Schechter, Jill Walker, Anita Midha, Keith E Steele, Paul B Robbins, Xia Li, Li Shi, John A Blake-Haskins, Ramy A Ibrahim, Laura Richman.

Drug Development

B006 Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy. George Fromm, Jason Rose, Taylor H Schreiber.

B007 Targeting the ubiquitin signaling system for cancer immunotherapy. Suresh Kumar, Liqing Wang, Jian Wu, Feng Wang, Saket Agarwal, Matthew Kodrasov, Wayne Hancock, Michael Mattern.

B008 Design and development of a novel series of PI3K-p110beta/delta-selective inhibitors with combined tumor immunotherapeutic, growth inhibition and anti-metastatic activity. Stephen J Shuttleworth.

B009 Design and development of HDAC6-selective inhibitors for hematological cancer treatment and solid tumor immunotherapy. Stephen J Shuttleworth.

B010 Pharmacodynamics and mechanisms of drug action for bispecific redirected T cell immunotherapy against P-cadherin. Justin Lucas, Andrea T Hooper, Jonathon Golas, Bryan Peano, Alan Opsahl, Leslie Obert, Maria Gavriil, Timothy Fisher, Anton Xavier, Michael Cinque, Roger Conant, Judy Lucas, Adam Root, Lioudmila Tchistiakova, Hans Peter Gerber, Chad May.

B011 Anti-TGFβ antibodies enhance NK receptor expression and effector mediated tumor cell killing with or without exogenous activating cytokines. Shireen S Khan, Zhilan Zheng, Llewelyn Lao, Ou Li, Amer M Mirza.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B012 Immunomodulated VTP enables cure of metastatic prostate and breast cancers in animal models. Dina Preise, Natasha Kudinova, Uri Lindner, Keren Sasson, Ronny Uzana, Jonathan Coleman, Yoram Salomon, Avigdor Scherz.

B013 A soluble form of CD80 enhances anti-tumor immunity by inhibiting PDL1 immune suppression and does not suppress via CTLA-4. Lucas Horn, Virginia Clements, Suzanne Ostrand-Rosenberg.

B014 BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy. Gro Gausdal, Kjersti Davidsen, Katarzyna Wnuk-Lipinska, Kathleen Wiertel, Monica Hellesøy, Magnus Blø, Lavina Ahmed, Linn Hodneland, Sergej Kiprijanov, Rolf A Brekken, James B Lorens.

B015 Antitumor activity of the CD122-biased immunostimulatory cytokine combined with immune checkpoint blockade requires innate and adaptive immunity. John L Langowski, Seema S Kantak, Rhoneil Pena, Yolanda Kirksey, Murali Addepalli, Steve Lee, Ute Hoch, Deborah H Charych, Stephen K Doberstein.

B016 Allogenic CAR T-cells for adoptive immunotherapy. Roman Galetto, Celine Lebuhotel, Isabelle Chion-Sotinel, Patricia Francon, Agnes Gouble, Julianne Smith.

B017 A soluble form of CD80 inhibits PD-L1 immune suppression and stimulates T cells through CD28-specific pathways indicating potential for increased therapeutic activity over checkpoint inhibition alone. Tiha M Long, Suzanne Ostrand-Rosenberg.

B018 Developmental and functional characterization of immunoglobulin kappa chain-bridged single chain bi-specific antibody for targeted anti-tumor therapy. Yu Hsun Lo, Jei-Hwa Yu, Yu-Hsen Hsui, Ta-Tung Yuan.

B019 Imprime PGG, a soluble β-glucan, binds to and activates dendritic cells resulting in enhanced T cell priming, expansion, and cytokine production. Ross B Fulton, Steven M Leonardo, Kyle S Michel, Michael E Danielson, Keith B Gorden, Jeremy R Graff.

B020 Effector cells in chitosan/interleukin-12 immunotherapy of bladder tumors in mice. Sean Smith, Jack Baltz, Bhanu Koppolu, Sruthi Ravindranathan, Khue Nguyen, David Zaharoff.

B021 Treatment with a novel targeting module, redirecting UniCAR T cells against PSCA, delays subcutaneous tumor growth and prolongs survival of tumor-bearing NSG mice. Elham Pishali Bejestani, Malte von Bonin, Marc Cartellieri, Armin Ehninger, Mechthild Krause, Michael Baumann, Gerhard Ehninger, Michael Bachmann.

B022 Functional bifurcation in T cells expressing chimeric antigen receptors. ZeNan L Chang, Pamela A Silver, Yvonne Y Chen.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B023 Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein based on Anticalin® technology. Marlon J. Hinner, Rachida-Siham Bel Aiba, Alexander Wiedenmann, Corinna Schlosser, Andrea Allersdorfer, Gabriele Matschiner, Christine Rothe, Ulrich Moebius, Shane A. Olwill.

B024 Single-chain traps targeting transforming growth factor-beta (TGF-beta) home to tumors and reduce tumor growth and metastasis by counteracting TGF-beta-mediated immunosuppression. John Zwaagstra, Traian Sulea, Anne E.G. Lenferink, Jason Baardsnes, Catherine Collins, Christiane Cantin, Lucie Couture, Limei Tao, Yves Durocher, Maureen O'Connor-McCourt.

B025 Integrin-targeted combination immunotherapy improves survival in a broad spectrum of tumor types. Byron H Kwan, Eric F Zhu, Harun R Sugito, Ahmed A Eltahir, Botong Ma, Alecia M Maragh, Mary K Delaney, Alice Tzeng, Cary F Opel, Glenn Dranoff, Jennifer R Cochran, K Dane Wittrup.

B026 Ubiquitin-conjugating enzyme E2C: a potential therapeutic target for primary and metastatic melanoma by microarray gene expression. Jenny Jimmy Hong, Kewei Gong, David Kaufman, Hsiaowang Chen, Richard Essner.

B027 Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Ali Roghanian, Ingrid Tiege, Linda Mårtensson, Kerry Cox, Claude Chan, Sjef Verbeek, Markus Hansson, Mats Jerkeman, Peter W.M. Johnson, Stephen Beers, Martin J Glennie, Björn Frendéus, Mark Cragg.

B028 Transcriptional and epigenetic signatures of ex vivo propagated three distinct TCR Vδ1, TCR Vδ2 and TCR Vδ3 cell subtypes with broad specificity for malignancies. Sourindra Maiti, Drew Deniger, Jianliang Dai, Laurence Cooper.

B029 The potent and selective phosphoinositide-3-kinase-gamma inhibitor, IPI-549, inhibits tumor growth in murine syngeneic solid tumor models through alterations in the immune suppressive microenvironment. Jeffery Kutok, Janid Ali, Erin Brophy, Alfredo Castro, Jonathan DiNitto, Catherine Evans, Kerrie Faia, Stanley Goldstein, Nicole Kosmider, Andre Lescarbeau, Tao Liu, Christian Martin, Karen McGovern, Somarajan Nair, Melissa Pink, Jennifer Proctor, Matthew Rausch, Sujata Sharma, John Soglia, Jeremy Tchaicha, Martin Tremblay, Vivian Villegas, Katherine Walsh, Kerry White, David Winkler, Vito Palombella.

B030 Structure-function studies of cytosolic DNA sensing pathway. PU GAO, Manuel Ascano, Thomas Zillinger, Winfried Barchet, Thomas Tuschl, Dinshaw J Patel.

B031 Heat-inactivated modified vaccinia virus ankara induces type I IFN and antitumor immunity via the cytosolic DNA-sensing pathway. Peihong Dai, Weiyi Wang, Cristian Serna-Tamayo, Dimitriy Zamarin, Stewart Shuman, Taha Merghoub, Jedd D Wolchok, Liang Deng.

B032 Targeting the PD-1/PD-L1 immune evasion axis with DNA aptamers. Aaron Prodeus, Jean Gariepy.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B033 Cytokine responses following intrapleural administration of oncolytic HSV SEPREHVIR® in patients with malignant pleural mesothelioma. Kirsty Learmonth, Lynne Braidwood, Penella Woll, Joe Conner.

B034 Preclinical immune antitumor activity of myeloid-targeting E7046 and Treg depleting E7777. Diana I Albu, Kuan-Chun Huang, Xingfeng Bao, Kenichi Nomoto, Mary Woodall-Jappe.


B035 Self-tumor-antigen-specific CD8 T cells were suppressed by regulatory T cells. Yuka Maeda, Hiroyoshi Nishikawa, Shimon Sakaguchi.

B036 Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Stéphanie Liénart, Julia Cuende, Michael Saunders, Bas van der Woning, Hans De Haard, Pierre G Coulie, Sophie Lucas.

B037 Improved CD8+ T-cell recognition of neuroblastoma after innate immune attack by Natural Killer cells. Lotte Spel, Jaap J Boelens, Dirk M van der Steen, Nina J.G. Blokland, Max M van Noesel, Jan J Molenaar, Mirjam H.M. Heemskerk, Marianne Boes, Stefan Nierkens.

Trials in Progress (promising ongoing trials or unique trial designs that have not yet yielded results)

B038 GMP production of cord blood-derived dendritic cell-based vaccine to prevent relapses after hematopoietic cell transplantation in children with AML. Colin de Haar, Ester Dunnebach, Maud C Plantinga, Nina JG Blokland, Stefan Nierkens, Jaap Jan Boelens.


B039 In silico models for B cell receptor signaling in chronic lymphocytic leukemia. Maria P. Frushicheva, Arup K. Chakraborty.

B040 Oncolytic measles virus for tumor vaccination. Stefan Hutzler, Stephanie Erbar, Robert A Jabulowsky, Tim Beissert, Jan Hanauer, Oezlem Tuereci, Rita Mitnacht-Kraus, Sebastian Kreiter, Mustafa Diken, Cedrik M Britten, Ugur Sahin, Michael D Muehlebach.




B041 A novel nanoparticular formulated tetravalent RNA cancer vaccine for treatment of patients with malignant melanoma. Robert A Jabulowsky, Carmen Loquai, Mustafa Diken, Lena M Kranz, Heinrich Haas, Sebastian Attig, Cedrik M Britten, Janina Buck, Evelyna Derhovanessian, Jan Diekmann, Isaac Esparza, Daniel Fritz, Yves Huesemann, Veronika Jahndel, Klaus Kuehlcke, Andreas N Kuhn, Peter Langguth, Ulrich Luxemburger, Martin Meng, Felicitas Mueller, Kerstin C Reuter, Doreen Schwarck, Kristina Spiess, Meike Witt, Jessica C Hassel, Jochen Utikal, Roland Kaufmann, Marc Schrott, Sebastian Kreiter, Sebastian Kreiter, Oezlem Tuereci, Christoph Huber, Christoph Huber, Ugur Sahin, Ugur Sahin, Ugur Sahin, Ugur Sahin.


B042 Regulation of Lck activity by a cryptic phosphosite. Adam H Courtney, Hanna E Sjolin-Goodfellow, Qinqin Ji, Theresa A Kadlecek, Arthur R Salomon, Arthur Weiss.

B043 Suppression of T cell responses by androgen deprivation drug leads to early relapse. Yang Pu.

B044 Indoleamine-2,3-dioxygense, the receptors for transforming growth factor beta and interferon gamma in resected melanoma: The presence, co-relation to the clinical variables and prognostic value. Maciej J Pelak, Dariusz Lange, Barbara Nikiel, Katarzyna M Pecka, Miroslaw Snietura.

B045 Immunosuppressive plasmocytes impede T-cell-dependent immunogenic chemotherapy. Shabnam Shalapour, Michael Karin.

B046 Mechanisms of T lymphocyte activation revealed by super-resolution microscopy. Maria Traver, Leonard Campanello, Suman Paul, Wolfgang Losert, Hari Shroff, Brian Schaefer.

B047 Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment. Roberto S Accolla, Greta Forlani, Giovanna Tosi.

Immunotherapy of Persistent Viral Infections and Virus-1 Induced Cancers

B048 The MHC class II transactivator CIITA inhibits the persistent activation of NF-kB by Human T cell Lymphotropic Virus type-1 Tax-1 oncoprotein. Greta Forlani, Rawan Abdallah, Roberto S Accolla, Giovanna Tosi.




B049 Evaluation of attenuated HSV1716 in combination with chimeric antigen receptor T cells for solid tumors. Samuel Haile, Joe Conner, Crystal Mackall.

B050 IFNγ signaling endows DCs with the capacity to control type I inflammation during parasitic infection through promoting T-bet+ regulatory T cells. Hyang-Mi Lee, Anne Fleige, Ruth Forman, Aly A Khan, Sunglim Cho, Ling-Li Lin, Duc T Nguyen, Asling O'Hara Hall, Christopher A Hunter, Werner Muller, Li-Fan Lu.

B051 Control of regulatory T (Treg) cell function by protein kinase C-eta (PKCη): A novel target for cancer immunotherapy. Christophe Pedros, Kok-Fai Kong, Amnon Altman.

B052 Donor derived cytotoxic antibodies from transplanted AML patients targeting a cell surface expressed nuclear antigen. Marijn Gillissen, Martijn Kedde, Etsuko Yasuda, Sophie Levie, Arjen Bakker, Yvonne Claassen, Martino Bohne, Dave Speijer, Daisy Picavet, Jan Stap, Pauline van Helden, Tim Beaumont, Hergen Spits, Mette Hazenberg.

B053 Designing chimeric antigen receptors for personalized immunotherapy: Rapid assembly of CARs from principal components using “EZ-CAR” platform. Ana Beatriz Korngold, Brian Rabinovich, Helen Huls, Laurence Cooper.

B054 Can CLL-B cells treated with novel combination therapies be used to promote anti-CLL immune responses? Joanne Davis, Kylie Mason, Chia Sharpe, Rachel Koldej, Brendon Chua, David Jackson, Paul Neeson, Constantine Tam, David Ritchie.

B055 The impact of rapamycin and tacrolimus treatment on resident CD8+ T-cell populations in cutaneous squamous cell carcinoma. Ji-Won Jung, Paul J Taylor, Fiona Simpson, Ian H Frazer, James W Wells.

B056 Modulation of cytokine secretion allows CD4 T cells secreting IL-10 and IL-17 to simultaneously participate in maintaining tolerance and immunity. Kanako Saito, Pascale Pignon, Maha Ayyoub, Danila Valmori.

B057 Optimizing the high throughput in vitro priming of tumor specific T cells. Lea Prokop, Stefanie Souczek, Janet Peper, Hans-Georg Rammensee, Stefan Stevanović.

B058 Expansion and activation of CD103+ DC progenitors at the tumor site promote T cell accumulation in melanoma lesions and transform clinical response to BRAF and PD-L1 blockade. Hélène Salmon, Juliana Idoyaga, Adeeb Rahman, Anna Karolina Palucka, Nina Bhardwaj, Florent Ginhoux, Miriam Merad.

B059 Slow maturation of early phagosomes promotes a TAP independent antigen cross-presentation pathway. Debrup Sengupta, Peter Cresswell.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B060 The canonical NF-κB pathway is crucial for Treg homeostasis during the antitumor response. Yenkel Grinberg-Bleyer, Hyunju Ho, Roland Schmid, Ulf Klein, Sankar Ghosh.

B061 Association of leukocyte inhibitory immunoglobulin-like transcript 3 (ILT3) with ovarian cancer and prevention of its expression by dietary supplementation of Ashwagandha (Withania somnifera). Natasha Gupta, Sameer Sharma, Seby L. Edassery, Janice M. Bahr, Lindsey Franklin, Erika Paulsen, Pincas Bitterman, Animesh Barua.

B062 Differences of transcriptional profiles between long-term tolerized and memory CD4 T cells. Naoko Imai, Takemasa Tsuji, Nasser K Altorki, Pei-Yu Kuo, Deepak Perumal, Samir Parekh, Sacha Gnjatic.

B063 Unsaturated fatty acids cause CD8+ T cell exhaustion in melanoma. Guoliang Cui, Susan Kaech.

B064 The effects of tumor-associated calreticulin mutants on antigen presentation. Najla Arshad, Peter Cresswell.

B065 The MHC:LILRB1 axis suppresses macrophage phagocytosis, and is a target for cancer immunotherapy. Roy L Maute, Kipp A Weiskopf, Aaron M Ring, Nan G Ring, Sydney R Gordon, Jonathan M Tsai, Kelly M McKenna, Po Yi Ho, Robin Z Cheng, James Y Chen, Irving L Weissman.

B066 PSGL-1, an immune checkpoint regulator that promotes T cell exhaustion in chronicviral infection and cancer. Roberto Tinoco, Florent Carrette, Monique L. Barraza, Jonathan Magaña, Marcus W. Bosenberg, Susan Swain, Linda M. Bradley.

B067 Successful immunotherapy of cancer stem cells requires memory and the adaptive immune system of the host. Patrick Schmidt, Nicolas Desbaillets, Pierre Dessen, Nancy Thompson, Joerg Huelsken, Dirk Jäger.

B068 Structural basis for Notch1 engagement of Delta-like 4 and Jagged1. Vincent C Luca, Kevin M Jude, Nathan W Pierce, Maxence V Nachury, Suzanne Fischer, K Christopher Garcia.

B069 Systemic alterations in T cell subpopulations of breast cancer patients. Mariana Pereira Pinho, José Alexandre Marzagão Barbuto.

B070 Characterization of covariables modulating CD33/CD3 BITE® antibody construct mediated cytotoxicity against primary AML cells. Christina Krupka, Peter Kufer, Roman Kischel, Gerhard Zugmaier, Thomas Köhnke, Felix Lichtenegger, Torben Altmann, Karsten Spiekermann, Binje Vick, Irmela Jeremias, Wolfgang Hiddemann, Gert Riethmüller, Marion Subklewe.

B071 Enhanced IL-12 production and T cell stimulation ability by dendritic cells matured in presence of GMP-grade Toll-like receptor ligands and IFN-γ. Lars Adamson, Dhifaf Sarhan, Bhavesh Choudhary, Jeroen Melief, Maria Nyström, Ulrika Edbäck, Renee Vermeij, Gina Scurti, Michael Nishimura, Andreas Lundqvist, Rolf Kiessling, Tanja Lövgren.

B072 Delineating the function/s of Runx1/3 in T cells and inflammation. Priya D.A Issuree, Dan R Littman.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B073 Structural basis of the 12-23 rule in V(D)J recombination. Heng Ru, Melissa G. Chambers, Maofu Liao, Hao Wu.

B074 Tumor-reactive CD4+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Sandy Pelletier, Simon Turcotte.

B075 CD103 integrin promotes T-cell recruitment and activation within epithelial tumors. Marie BOUTET, Fathia MAMI-CHOUAIB.

B076 Novel use of Listeria and gemcitabine to improve immunotherapy for pancreatic cancer. Dinesh Chandra, Wilber Quispe-Tintaya, Arthee Jahangir, Alice Kwon, Rodrigo Alves da Silva, Lukman Solola, Ziqiang Yuan, Steven K Libutti, Claudia Gravekamp.

B077 Evaluating oncolytic vaccines targeting mutated epitopes in a murine fibrosarcoma model CMS-5. Kyle Stephenson, Matthew Atherton, John Bell, Brian Lichty.

B078 Ganglioside containing nano-proteoliposome reduces number of myeloid-derived suppressor cells: First clinical evidences in metastatic renal cancer patients. Liliana Oliver, Raquel Diaz, Maura Rabade-Chediak, Audry Fernández, Rydell Alvarez, Eva Salomon, Leslie Perez, Daymys Estevez, Yoisbel Moreno, Luis E Fernández, Circe Mesa.

B079 In vivo tracking of B cell-T cell interactions in the germinal center. Giulia Pasqual, Jeroen Tas, Gabriel Victora.

B080 PIN-2, a novel immunomodulatory peptide. Joshua B Goldberg, Sophie J Hanscom, Kenneth Gorelick, Colin B Bier.

B081 Tissue repair function of regulatory T cells during infection and cancer progression. Wei Hu, Nicholas Arpaia, Paula D Bos, Jesse Green, Alexander Rudensky.

B082 Reovirus treated NK cells exhibit enhanced cetuximab mediated antibody-dependent cellular cytotoxicity against colorectal cancer cell lines. Xing Zhao, Narendiran Rajasekaran, Cariad Chester, Atsushi Yonezawa, Suparna Dutt, Matt Coffey, Holbrook Kohrt.

B083 Human tumor-based identification of immune checkpoint targets. Thomas McQuade, Yanyan Wang, Daniel Doty, Najmia Amirina, Sri Vadde, Hareesh Chamarthi, Cokey Nguyen, Sheila Ranganath, Jennifer Watkins-Yoon.

B084 A comparison of human CMVpp65-specific central memory and effector memory CD8 T cells stimulated in vivo with IL-2 or IL-15/IL15Rα complex in a murine xenograft model of adoptive cell therapy. Tzu-yun Kuo, Aisha Hasan, Richard J O'Reilly.

B085 Interactions of regulatory T cells with the lung tumor microenvironment and effects on the anti-tumor immune response. Jesse A Green, Alexander Y Rudensky.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B086 Tumor derived CD103+ dendritic cells carry antigen to the tumor draining lymph node and are essential for CD8+ T cell priming. Edward Roberts, Miranda Broz, Matthew Krummel.

B087 Cyclic dinucleotide: A novel adjuvant for squamous cell carcinoma. Shekhar K Gadkaree, Rupashree Sen, Juan Fu, Clint Allen, Young J Kim.

B088 Can the pro-tumorigenic activity of Th17 cells be a therapeutic opportunity? Nicola Gagliani, Carolina Amezcua Vasely, Hao Xu, Samuel Huber, Richard Flavell.

B089 Macrophage-mediated trogocytosis leads to death of antibody-opsonized tumor cells. Ramraj Velmurugan, Dilip Challa, Sripad Ram, Raimund Ober, E. Sally Ward.

B090 A Toll-like receptor 5 agonist entolimod as a potential anticancer immunotherapeutic agent. Craig Brackett, Bojidar Kojouharov, Sandra Gollnick, Andrei Gudkov, Lyudmila Burdelya.

B091 Demonstration of systemic antitumor immunity via intratumoral regulated expression of IL-12 as a gene therapy approach to treatment of cancer. John A Barrett, Tim Chan, Hongliang Cai, John Miao, Suma Krishnan, Francois Lebel.

B092 Targeting phosphatidylserine synergizes with immune checkpoint blockade by inhibiting multiple immune suppressive mechanisms. Xianming Huang, Jian Gong, Dan Ye, Van Nguyen, Shen Yin, Carrie Baldwin, Rolf Brekken, Steve King, Jeff Hutchins, Bruce Freimark.

B093 Citrullinated vimentin is a novel tumor rejection target for CD4 T cells. Lindy Durrant, Victoria Brentville, Wei Xue, Rachael Metheringham.

B094 Intratumoral administration of IMO-2125, a novel TLR9 agonist, modulates the tumor microenvironment and exerts systemic antitumor activity alone and in combination with an anti-CTLA-4 mAb. Daqing Wang, Fugang Zhu, Xianzhi Mao, Sudhir Agrawal.

Immunotherapy of Persistent Viral Infections and Virus-1 Induced Cancers

B095 Targeting Epstein-Barr virus transformed B lymphoblastoid cells using antibodies with T cell receptor-like specificities. Junyun Lai, Wei Jian Tan, Chien Tei Too, Nalini Srinivasan, Lan Hiong Wong, Fatimah Mustafa, Soh Ha Chan, Jianzhu Chen, Paul Anthony MacAry.

B096 Oncolytic vaccination for HPV induced cancer. Matthew J Atherton, Kyle B Stephenson, Yonghong Wan, David F Stojdl, Brian D Lichty.

B097 CD8 T cells reinvigorated by PD-1 pathway blockade become re-exhausted by continual antigen exposure. Kristen E Pauken, Pamela M Odorizzi, Bertram Bengsch, Jason M Schenkel, E John Wherry.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B098 Discovering immunotherapeutic T-cell epitopes for HPV16-associated cancers. Sri Krishna, Jacqueline Nelson, Falguni Parikh, Amelia Clark, Seunghee Kim-Schulze, Marshall Posner, Andrew Sikora, Karen S Anderson.

B099 Immortalized HMy2/solid tumor hybridomas induce two different tumor antigen-specific T cell clones in vitro. Yehia Mohamed, Michael Browning.

B100 A bank of EBV-specific T-cells of defined HLA type and HLA restriction: “Off the shelf” treatment for rituximab refractory EBV+ B-cell lymphomas in hematopoietic and organ allograft recipients. Richard J O'Reilly, Ekaterina Doubrovina, Karim Baroudy, Farid Boulad, Nancy A Kernan, Ramzi Khalaf, Esperanza B Papadopoulos, Craig Sauter, Victoria Szenes, Stephanie Suser, Gloria Wasilewski, Julianna Ruggierio, Susan E Prockop.

Imaging and Targeting of the Antitumor Response

B101 Engineered PD-1 variants as immunotherapies for cancer. Sydney R Gordon, Roy Maute, Aaron Mayer, Melissa McCracken, Arutselvan Natarajan, Nan Guo, Richard Kimura, Jonathan M Tsai, Aashish Manglik, Andrew Kruse, Sanjiv Gambhir, Irving L Weissman, Aaron M Ring.

B102 Releasing oxygen-restricted CTL function: Insights from live intratumoral imaging. Tali Feferman, Yoav Manaster, Yael Gruper, Zohar Shipony, Guy Shakhar.

B103 Transparent tumor tomography (T3): Spatial 3D mapping of immune responses in a whole tumor after immunotherapy. Steve Seung-Young Lee, Vytas Bindokas, Stephen J Kron.

B104 Characterization and specificity analysis of tumor infiltrating lymphocytes in ovarian carcinoma. Janet Kerstin Peper, Kevin Röhle, Heiko Schuster, Philipp Wagner, Hans-Georg Rammensee, Stefan Stevanovic.

B105 FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Rony Dahan, Emanuela Sega, John Engelhardt, Mark Selby, Alan J Korman, Jeffrey V Ravetch.

B106 Noninvasive imaging of immune responses. Mohammad Rashidian.

B107 In vivo mouse breast cancers-xenograft imaging with radiolabeled recombinant Flagellin. guihua hou.

B108 Design of a chimeric antigen receptor (CAR) with controllable function via small molecule. alexandre Juillerat, Alan Marechal, Jean Marie Fihol, Anne-sophie Gautron, Julien Valton, Laurent Poirot, Philippe Duchateau.

B109 In-depth Tissue Analysis Using Multiplexed Immunohistochemical Consecutive Staining on Single Slide. Romain Remark, Taha Merghoub, Diane Damotte, Jedd D Wolchok, Miriam Merad, Sacha Gnjatic.



Preclinical Models

B110 The combination of TLR7/8 agonists and carbon ion radiation induces local and abscopal immune responses in gastrointestinal tumors in vivo. Peter E Huber, Ramon Lopez, Alexandra Tietz, Nils Nicolay, Thuy Trinh, Sisombath Sonevisay.

B111 Oncolytic adenoviruses targeting transforming growth factor-β for the treatment of breast cancer bone metastases: Addressing the in vivo barriers. Yuefeng Yang, Weidong Xu, Charles Brendler, Li-Sheng Wang, Bellur Prabhakar, Prem Seth.

B112 Identifying determinants of melanoma response to immune checkpoint inhibitors via preclinical modeling. Chi-Ping Day, Rajaa El Meskini, Cari Graff-Cherry, Aleksandra Michalowski, Zoe Weaver Ohler, Terry Van Dyke, Glenn Merlino.

B113 In vivo characterization of anti-PD-1 antibody REGN2810 in human PD-1 knock-in mice. Elena Burova, Omaira Allbritton, William Poueymirou, Venus Lai, Janelle Waite, Dimitris Skokos, Nicholas Papadopoulos, Drew Murphy, Israel Lowy, Ella Ioffe, Gavin Thurston.

B114 Evaluation of the antitumor activity and molecular characterization of mouse syngeneic tumor models in response to anti-PD-1 treatment as a single agent and in combination with approved agents. Heather Hirsch, Ruban Mangadu, Mingmei Cai, Yanhong Ma, Uyen Phan, Yaolin Wang, Venkataraman Sriram, Joseph H Phillips, Terri McClanahan, Brian Long, Elaine M Pinheiro.

B115 Application of small animal image-guided irradiation to a preclinical bioluminescent syngeneic metastatic breast cancer model in combination with immunotherapy to inform on combination strategies. Andrew McKenzie, Nektaria Papadopoulou, Yin Yinfei, Simon Jiang, Jane Wrigley, Jason King, Shonna Glenn, Qian Shi, Rajendra Kumari.

B116 Antibody-mediated blockade of phosphatidylserine combined with intense radiation improves survival and tumor eradication in rat models of non-small cell lung cancer. Olivier Belzile, Zhang Zhang, Xianming Huang, Debabrata Saha, Rolf A Brekken.

B117 Profiling of syngeneic models by check point inhibitors, RNAseq, and FACS analysis enable better selection of models for immune targeted combination therapy. Lan Zhang, Juan Zhang, Qian Shi.

B118 Preclinical model of patient-derived tumor transplant in humanized mice for cancer immunotherapy. Annika Wulf-Goldenberg, Maria Stecklum, Iduna Fichtner, Jens Hoffmann.

B119 Deciphering CD20 immunogenicity to generate protective anti-tumor CD4+ and CD8+ T cells. Sophie Siberil, Benoit Milcent, Quentin Riller, Claire Deligne, Mohamad Hamieh, Olivier Toutirais, Jean-Baptiste Latouche, Jean-Luc Teillaud.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B120 Characterization and combination immunotherapy treatment of an inducible autochthonous murine lung cancer model expressing human carcinoembryonic antigen (CEA) as a tumor-associated self-antigen. Eric F Zhu, Kavya Rakhra, Naveen Mehta, Kelly D Moynihan, Cary F Opel, Darrell J Irvine, K. Dane Wittrup.

B121 Low dose, metronomic cyclophosphamide therapy sensitizes tumors to CpG-1826 immunotherapy in a preclinical glioma model. Marie Jordan, David J Waxman.

B122 A preclinical mouse model to assess antitumor efficacy and development of immune related adverse events (irAEs) following combination immunotherapies. Jing Liu, Stephten J. Blake, Kirsten A. Fairfax, Michelle C.R. Yong, Stacey Allen, Mark J. Smyth, Michele W.L. Teng.

B123 In vivo targeting of antigen into XCR1+ DC combined with a potent amplification regime induces massive antigen-specific CD8+ T cell cytotoxicity. Yi Yang, Evelyn Hartung, Anika Jäkel, Stephanie Gurka, Hans W Mages, Richard A. Kroczek.

B124 Immunotherapy of acute myeloid leukemia using Vg9Vd2 T-cells. Ana C Parente-Pereira, Lynsey M Whilding, Pramila Krishnamurthy, Richard Beatson, Tomasz Zabinski, Linda Barber, Farzin Farzaneh, Ghulam Mufti, John Maher.

B125 Antigen density determines the efficacy of chimeric antigen receptor (CAR) re-targeted T-cells. David Marc Davies, Solange Paredes-Moscosso, Satyen Gohil, Marco Della-Peruta, Vania Coelho, Amit Nathwani.

B126 Regeneration of tumor antigen specific CTLs utilizing iPSC technology. Takuya Maeda, Seiji Nagano, Hiroshi Ichise, Kyoko Masuda, Toshio Kitawaki, Akifumi Kondo-Takaori, Hiroshi Kawamoto.

B127 Tumor eradication in a murine model of glioma with vaccination and anti-CTLA-4 but not anti-PD-1. Cameron S Field, Martin K Hunn, Peter M Ferguson, Hideo Yagita, Ian F Hermans, Lindsay R Ancelet.

B128 Chimeric antigen receptor transduced gamma delta T lymphocytes provide enhanced tumor specificity. Jonathan Fisher, anna capsomidis, Barry Flutter, Gabriel Benthal, Rebcca wallace, Kenth Gustafsson, Karin Straathof, Martin Pule, John Anderson.

B129 Chimeric antigen receptor T-cells targeting the αvβ6 integrin demonstrate potent antitumor activity in multiple solid tumors. Lynsey May Whilding, Ana C Parente-Pereira, Tomasz Zabinski, David M Davies, Roseanna Petrovic, Shelia Violette, Sadaf Ghaem-Maghami, Sabari Vallath, John Marshall, John Maher.

B130 Evaluation of novel metronomic chemotherapy and cancer vaccine combinatorial strategy. Maria Tagliamonte, Annacarmen Petrizzo, Maria Lina Tornesello, Antonio Luciano, Domenica Rea, Antonio Barbieri, Claudio Arra, Maria Napolitano, Gennaro Ciliberto, Luigi Aurisicchio, Claudio Coscia, Franco M. Buonaguro, Luigi Buonaguro.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B132 A model of de novo acute myeloid leukemia with an autologous human immune system as a preclinical tool for testing immunotherapies. Mandeep Kaur, Amanda Hanson, Adam Drake, Ryan Phennicie, Jianzhu Chen.

B133 In vivo imaging of innate immune cells to measure drug response. Miles A Miller, Mikael Pittet, Ralph Weissleder.

B134 Profiling compounds in human primary cell BioMAP® systems for drug discovery and development in cancer immunotherapy. Alison O'Mahony, Jason Ptacek, Jennifer Melrose, Karen Matta, Ellen Berg.

B135 PD-L1 inhibition is an effective adjuvant for targeting PD-L1 expressing cancer cells when combined with a whole tumor cell vaccine and CTLA-4 checkpoint blockade. Anthony D Sandler, Clifford Morgan, Priya Srinivasan.

B136 Development of PD-L1/L2 over-expressing mouse liver cancer models to test the efficacy of anti-PD1 therapy for hepatocellular carcinoma. Da-Liang Ou, Shu-Ching Chen, Yu-Chia Su, Ann-Lii Cheng, Chiun Hsu.

B137 Inhibition of TGF-beta1 and 2 facilitates therapeutic tumor vaccine efficacy. Masaki Terabe, Faith C Robertson, Shingo Kato, Emma De Ravin, Katharine Clark, Anja Bloom, Amer M Mirza, Jay A Berzofsky.


B138 Single low-dose administration of anti-CTLA-4/tremelimumab at the tumor excision site boosts systemic antitumor immunity in early-stage melanoma patients: Results from a Phase-1 study. Anita G.M. Stam, Kim M. van Pul, Bas D. Koster, Dafni Chondronasiou, Sinéad M. Lougheed, M. Petrousjka van den Tol, Karin Jooss, Ronald J.C.L.M. Vuylsteke, Alfons J.M. van den Eertwegh, Tanja D. de Gruijl.

B139 Toxicity testing of EGFRvIII CAR-based immunotherapy of glioblastoma: From bench to bedside. Alexandria P Cogdill, Alina Boesteanu, Chong Xu, Kathleen Haines, John Scholler, Joseph Fraietta, Yangbing Zhao, Xiaojun Liu, Jennifer Morrissette, Bruce Levine, Simon Lacey, Andreas Loew, Reshma Singh, Jennifer Brogdon, Donald M O'Rourke, Marcela V Maus, Carl H June, Laura A Johnson.

B140 Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2. Michael K.K. Wong, Michael A Morse, David F McDermott, Joseph I Clark, Howard L Kaufman, Gregory A Daniels, Hong Hua, Sandra Aung.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B141 Combining the telomerase peptide cancer vaccine UV1 with CTLA-4 blockade in patients with metastatic malignant melanoma: Proof of principle and early clinical reports from a phase I/IIa trial. Elin Aamdal, Tormod Kyrre Guren, Else Marit Inderberg Suso, Gunnar Kvalheim, Jon Amund Kyte, Øyvind Kongstun Arnesen, Steinar Aamdal, Gustav Gaudernack.

B142 Immunoprofiling head and neck cancer: Preliminary data of the IRECT trial (Immune response evaluation to curative conventional therapy). Simon Laban, Marie-Nicole Theodoraki, Daniel Fürst, Joannis Mytilineos, Ramin Lotfi, Djordje Atanackovic, Tim Luetkens, Thomas K Hoffmann.

B143 A phase 1a/1b study of FPA008 in combination with nivolumab in patients with selected advanced cancers. Julie Brahmer, Drew Rasco, Minjia Chen, Emma Masteller, Ibrahim Qazi, Seema Rogers, Neil Sankar, Robert Sikorski, Julie Hambleton, F. Stephen Hodi.

B144 Reduction of minimal residual disease in pediatric B-precursor acute lymphoblastic leukemia by an Fc-optimized CD19 antibody. Ursula Joerdis Eva Seidel, Ludger Grosse-Hovest, Ludger Grosse-Hovest, Patrick Schlegel, Martin Hofmann, Martin Hofmann, Friedhelm R Schuster, Roland Meisel, Kai-Erik Witte, Steffen Aulwurm, Steffen Aulwurm, Elwira Pyz, Hans-Georg Rammensee, Hans-Georg Rammensee, Gundram Jung, Gundram Jung, Rupert Handgretinger, Rupert Handgretinger, Peter Lang, Peter Lang.

B145 Phase I study of hTERT and IL-12 DNA immunotherapy with electroporation in patients with solid tumors after surgery and adjuvant therapy. Robert H. Vonderheide, Charu Aggarwal, David L. Bajor, Jessica Goldenberg, Jessica C. Lee, Jian Yan, Matthew P. Morrow, Angela DeMichele, Corey J. Langer, Peter J. O'Dwyer, David B. Weiner, Zandong Yang, Mark L. Bagarazzi.

B146 Next-generation dendritic cell vaccination in postremission therapy of AML: Results of a clinical phase I trial. Felix S Lichtenegger, Frauke M Schnorfeil, Thomas Köhnke, Torben Altmann, Veit Bücklein, Andreas Moosmann, Monika Brüggemann, Beate Wagner, Wolfgang Hiddemann, Iris Bigalke, Gunnar Kvalheim, Marion Subklewe.

B147 Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with recurrent prostate cancer (NCT01341652). Douglas G. McNeel, Lawrence Fong, Emmanuel S. Antonarakis, Glenn Liu.


B148 The inflammatory microenvironment of luminal breast tumors re-shapes CCR7-driven metastatic spread. Polina Weitzenfeld, Olga Kossover, Cindy Korner, Tsipi Meshel, Stefan Wiemann, Dror Seliktar, Daniel F. Legler, Adit Ben-Baruch.

B149 mTOR as a novel therapeutic target for GM-CSF mediated myeloid cell suppression. Karrie K Wong, Glenn Dranoff.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B150 Juxtacrine signaling between the tumor-associated macrophages and the breast cancer stem cells contribute to the cancer stem cell niche by inducing a cytokine signaling network. Haihui Lu, Wai Leong Tam, Vera Donnenberg, Xin Ye, Rohit Bhargava, Robert Weinberg.

B151 The role of integrin αvβ6 in regulating the tumor immune response in head and neck cancer. Karwan A Moutasim, Hollie Robinson, Jason Fleming, Emma King, Christian Ottensmeier, Gareth Thomas.

B152 Increasing the antitumor efficacy of immunotherapy in melanoma by using topoisomerase I inhibitors. Jodi A McKenzie, Rina M Mbofung, Shruti Malu, Patrick Hwu.

B153 The checkpoint regulator PD-1 inhibits NK cell responses to tumors. Michele Ardolino, Joy Hsu, Camillia S. Azimi, Troy N. Trevino, Thornton W. Thompson, Lily Zhang, Alexandre Iannello, David H. Raulet.

B154 Immune surveillance is thwarted by tumor-cell intrinsic β-catenin signaling. Stefani Spranger, Brendan Horton, Thomas F. Gajewski.

B155 Anti-CD137 mAb therapy of multiple myeloma. Camille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, David Ritchie, Marta Chesi, Leif Bergsagel, Geoffrey R Hill, Ludovic Martinet, Mark J Smyth.

B156 Tumor high endothelial venules (HEVs), specialized blood vessels which recruit lymphocytes to limit tumor progression. Robin Laffont, Fanny Lafouresse, Jean-Philippe Girard.

B157 OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer. Massimo Di Nicola, Roberta Zappasodi, Alessia Burocci, Giusi Ruggiero, Fabio Martinelli, Claudio Tripodo, Domenica Lorusso, Filippo De Braud, Francesco Raspagliesi, Mario P Colombo.

B158 Cyclin Dependent Kinase-5 regulates IFNγ induced PD-L1 expression via IRF-1 in Medulloblastoma. Rodney Dixon Dorand, Agne Petrosiute, Joseph Nthale, Tej Pareek, Francesca Scrimieri, Jay Myers, Deborah Barkauskas, John J Letterio, Duncan S Stearns, Alex Y. Huang.

B159 Modulation of checkpoint expression in tumor microenvironment by intratumoral administration of a novel TLR9 agonist: Rationale for combination therapy. Wayne Jiang, Daqing Wang, Fugang Zhu, Lakshmi Bhagat, Jillian DiMuzio, Sudhir Agrawal.

B160 Matrix metalloproteinase-2 modulates inflammation and melanoma progression via TLR2. Mansi Saxena, Luciana R Muniz, Nina Bhardwaj.

B161 Mechanisms underlying the induction of natural killer cell exhaustion in metastatic melanoma. Elena Gonzalez-Gugel, Shaheen Ensanyat, Adiel Munk, Nina Bhardwaj.

B162 Comprehensive analyses of tumor immunity with implications to cancer immunotherapies. Bo Li, Jun Liu, X. Shirley Liu.

B163 TLR7/TLR8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Zhixia Zhou, Xin Yu, Jian Zhang, Cai Zhang.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B164 Calreticulin expression by non-small-cell lung cancer correlates with signs of immunosurveillance and favorable prognosis. Jitka Fucikova, Etienne Becht, Jeremy Goc, Kris Iribarren, Romain Remark, Diane Damotte, Marco Alifano, Priyanka Devi, Wolf Herve Fridman, Marie-Caroline Dieu-Nosjean, Guido Kroemer, Catherine Sautes Fridman, Isabelle Cremer.

B165 Characterizing the role of macrophages in breast cancer cell extravasation in 3D microfluidic models. Alexandra Boussommier, Roger D Kamm.

B166 Dendritic cells in the tumor microenvironment support T-ALL growth through IGF1R activation. Todd A Triplett, Kim T Cardenas, Hilary Selden, Lauren I.R. Ehrlich.

B167 CXCR1/IL-8 signaling promotes hematopoietic stem and progenitor cell engraftment in the developing zebrafish. Bradley W Blaser, Jessica Moore, Brian Li, Owen Tamplin, Vera Binder, Leonard I Zon.

B168 The role of the danger-associated molecule HMGB-1 in inflammatory responses and the induction of cancer. Maureen Ann Cox, Bryan Snow, Drew Wakeham, Jillian Haight, Annick You-Ten, Tak Mak.

B169 Matrix Metalloproteinase-2 and Toll-Like Receptors modulating immune responses in the tumor microenvironment. Luciana Ribeiro Muniz, Mansi Saxena, Nina Bhardwaj.

B170 Blockade of checkpoint programmed death 1 (PD1) delays tumor growth and induces early transferable protective immunity in a murine orthotopic pancreatic ductal adenocarcinoma model. Marcela d'Alincourt Salazar, Edwin Manuel, Weimin Tsai, Massimo D'Apuzzo, Leanne Goldstein, Bruce R. Blazar, Don J. Diamond.

B171 A novel tumor-microenvironment-based prognostic score in patients with primary operable colorectal cancer. James H Park, Donald C McMillan, Joanne Edwards, Paul G Horgan, Campbell SD Roxburgh.

B172 Oncogene-mediated immune microenvironments in lung cancer provide a rationale for combination therapies. Lauren S Havel, Dingcheng Gao, Nasser Altorki, Vivek Mittal.

B173 Distinct microenvironment of invasion tumor front impedes the immune efficacy for brain tumor. Chiu-Ming Lin, Chi-Shiun Chiang.

B174 FOXP3+CD4+ T-cell subpopulations distinctly control the prognosis of colorectal cancers. Takuro Saito, Hiroyoshi Nishikawa, Hisashi Wada, Masaki Mori, Yuichiro Doki, Shimon Sakaguchi.

B175 Tumor microenvironment acts direct and systemically skewing blood monocytes into suppressive CD163highIL-10high cells that impact in breast cancer patients’ survival. Rodrigo N Ramos, Céline Rodriguez, Sophie Léon, Isabelle Treilleux, Carola Ries, Emilie Lavergne, Sylvie Chabaud, Christophe Caux, José AM Barbuto, Nathalie Bendriss-Vermare, Christine Ménétrier-Caux.


Translating Science into Survival September 16 - 19, 2015 • Sheraton New York Times Square Hotel • New York, NY Poster Session B, Friday, September 18, 2015, 4:45 p.m.-6:45 p.m. B176 Integrative analysis of the immune landscape of CRC liver metastases. Zeynep Kosaloglu, Inka Zörnig, Niels Halama, Eliana Ruggiero, Jürgen Weitz, Alexis Ulrich, Moritz Koch, Christoph Kahlert, Fee Klupp, Benedikt Brors, Dirk Jäger.

B177 Exploration of the signaling pathways triggered by exogenous galectin-9 in human T and B cells. Claire Lhuillier, Clement Barjon, Toshiro Niki, Aurore Gelin, Nadira Delhem, Mitsuomi Hirashima, Ming Wei, Olivier Dellis, Pierre Busson.

B178 4-methylumbelliferone modulates tumor microenvironment improving the antitumor efficacy of combined gene based- immunotherapy in murine colon adenocarcinoma. Mariana Malvicini, Esteban Fiore, Valentina Ghiaccio, Flavia Piccioni, Miguel Rizzo, Mariana Garcia, Marcelo Rodriguez, Juan Bayo, Estanislao Peixoto, Catalina Atorrasagasti, Laura Alaniz, Pablo Matar, Guillermo Mazzolini.

B179 Enhancing intratumoral Treg depletion through antibody engineering and analysis of the checkpoint landscape of mouse and human cancers. Frederick Arce Vargas, Andrew J Furness, Marta H Lesko, Martin Pule, Jeffrey V Ravetch, Karl S Peggs, Sergio A Quezada.

B180 Cytokine regulation of PD-L1 expression on tumor-associated myeloid cells. Genevieve Hartley, Dan Regan, Amanda Guth, Steven Dow.

B181 Genetic engineering of tumor-infiltrating monocytes to inhibit primary and metastatic breast cancer. Giulia Escobar, Davide Moi, Ryan Galea, Moustafa Sherif, Anna Ranghetti, Luigi Naldini, Roberta Mazzieri.

B182 IGN004 is an antibody-interferon-alpha fusion protein against a novel tumor-associated antigen with both direct antitumor and immunostimulatory effects. Kristopher Steward, Michael Gresser, Raj Sachdev, Sanjay Khare.

B183 Treg inhibition by anti-GITR therapy evokes therapeutic antitumor responses selectively in the context of a pro-inflammatory tumor microenvironment. Roberta Zappasodi, Sadna Budhu, Cailian Liu, Kyle Draleau, David Schaer, Hong Zhong, Xia Yang, Taha Merghoub, Jedd D Wolchok.

B184 Targeting autophagy restores natural killer cell-mediated antitumor immune response under hypoxic stress. Takouhie Mgrditchian, Tsolere Arakelian, Elodie Viry, Muhammad Zaeem Noman, Salem Chouaib, Guy Berchem, Bassam Janji.

B185 Induction of specific immunity to MUC1 antigen by tumor irradiation and cancer vaccines in murine tumor models. Gilda Gali Hillman, Matthew D. Fountain, Shoshana E. Rothstein, Lyndsey Reich, Lisa Abernathy, Christopher K. Yunker, Fulvio Lonardo, Philippe Slos.